The article on pan PI3K inhibitor prodrug for cancer therapy in the January 1, 2008 issue of Cancer Research (1) should have included the following conflict of interest statement: D.L. Durden would like to disclose a financial interest in Semafore Pharmaceuticals. The terms of the arrangement have been reviewed and approved by Emory University in accordance with the conflict of interest policies.

1
Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu H-K, Peng Q, Durden DL. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Cancer Res
 
2008
;
68
:
206
–15.
View Original Article
©2008 American Association for Cancer Research.
2008